Skip to main content
SpringerLink
Log in

Vedolizumab cost effective for active UC in UK

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. National Health Service

  2. 2012/2013 British pounds

Reference

  • Wilson MR, et al. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. European Journal of Health Economics : 8 Mar 2017. Available from: URL: http://dx.doi.org/10.1007/s10198-017-0879-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vedolizumab cost effective for active UC in UK. PharmacoEcon Outcomes News 774, 29 (2017). https://doi.org/10.1007/s40274-017-3853-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3853-7

Search

Navigation